Nguyen Kha Minh, Tran Hai Phuong Nguyen, Dang Vi Tuong, Hoang Sy Van
Department of Internal Medicine, Faculty of Medicine, University of Medicine and Pharmacy at Ho Chi Minh City, No. 217, Hong Bang Street, Ward 11, District 5, Ho Chi Minh City 700000, Vietnam.
Department of Cardiology, Cho Ray Hospital, No. 201B, Nguyen Chi Thanh Street, Ward 12, District 5, Ho Chi Minh City 700000, Vietnam.
Eur Heart J Case Rep. 2024 Mar 12;8(4):ytae125. doi: 10.1093/ehjcr/ytae125. eCollection 2024 Apr.
The persistent challenge of high mortality rates in acute myocardial infarction-induced cardiogenic shock endures notwithstanding advancements in the diagnosis and treatment of this disease over the past two decades. While recent studies present conflicting evidence on the efficacy of veno-arterial extracorporeal membrane oxygenation (VA ECMO), observational research supports the benefits of early VA ECMO initiation. However, the current lack of robust support from randomized clinical trials for VA ECMO use in this context highlights the ongoing uncertainty surrounding its effectiveness.
A 52-year-old male with sudden, intense chest pain was diagnosed with cardiogenic shock due to non-ST-elevation acute myocardial infarction at a local hospital. Initial treatment included aspirin, clopidogrel, and noradrenaline. Upon transfer to our hospital, the patient's condition deteriorated, leading to acute respiratory distress and severe hypotension. Prior to emergent percutaneous coronary intervention, peripheral VA ECMO was initiated. Coronary angiography revealed left main coronary artery occlusion, and a successful intervention was performed. Post-intervention, the patient's haemodynamic parameters significantly improved, and after 7 days, ECMO was successfully discontinued. The patient was discharged in stable condition after 25 days, with favourable outcomes persisting at the 30-day mark. Continuous monitoring is planned during outpatient follow-up.
The clinical case illustrates a successful treatment outcome achieved through teamwork by the heart team, supporting the efficacy of the VA ECMO pre-percutaneous coronary intervention approach. The careful selection of appropriate candidates and strategic initiation of VA ECMO may play a role in enhancing outcomes for individuals experiencing acute myocardial infarction complicated by challenging cardiogenic shock.
尽管在过去二十年中,急性心肌梗死所致心源性休克的诊断和治疗取得了进展,但高死亡率这一持续挑战依然存在。虽然近期研究对于静脉-动脉体外膜肺氧合(VA ECMO)的疗效提供了相互矛盾的证据,但观察性研究支持早期启动VA ECMO的益处。然而,目前在这种情况下VA ECMO的使用缺乏随机临床试验的有力支持,这凸显了围绕其有效性的持续不确定性。
一名52岁男性突发剧烈胸痛,在当地医院被诊断为非ST段抬高型急性心肌梗死所致的心源性休克。初始治疗包括阿司匹林、氯吡格雷和去甲肾上腺素。转至我院后,患者病情恶化,出现急性呼吸窘迫和严重低血压。在紧急经皮冠状动脉介入治疗前,启动了外周VA ECMO。冠状动脉造影显示左主干冠状动脉闭塞,并成功进行了介入治疗。介入治疗后,患者的血流动力学参数显著改善,7天后,ECMO成功撤机。患者在25天后病情稳定出院,30天时仍有良好预后。门诊随访期间计划进行持续监测。
该临床病例说明了心脏团队通过团队合作取得的成功治疗结果,支持了在经皮冠状动脉介入治疗前采用VA ECMO的疗效。仔细选择合适的患者并战略性地启动VA ECMO可能有助于改善急性心肌梗死合并具有挑战性的心源性休克患者的预后。